A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
Sarepta Therapeutics, Inc.
Phase 1 study testing SRP-1005 in Huntington's disease.
RecruitingPhase 1DrugClinicalTrials.govTreatment trial
Recruiting in: Birmingham, Cardiff, Christchurch +5 more (Australia, New Zealand, South Korea +2 more)
Preparing a short plain-English summary.
